#United States Neurological Biomarkers Market news | Explore Tumblr posts and blogs

exp-market-research111 · 7 days ago

Text

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Report 2024

In the United States, around 1 million people are living with multiple sclerosis. Out of these, 80-85% of people diagnosed with multiple sclerosis have relapsing-remitting multiple sclerosis (RRMS), making it the most common sub-type. Therefore, researchers are emphasizing developing high-quality and potent drugs to manage the disease effectively.

Read Full Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/relapsing-remitting-multiple-sclerosis-drug-pipeline-insight

This blog provides an in-depth exploration of the relapsing-remitting multiple sclerosis (RRMS) drug pipeline, focusing on market dynamics, external trends, segmentation, growth opportunities, and the impact of COVID-19. Key players like Celgene, Hoffmann-La Roche, Hikma Pharmaceuticals LLC, and Biogen are driving advancements in the development of innovative treatments for this condition.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Overview

Relapsing-remitting multiple sclerosis (RRMS) is a neurological condition characterized by episodes of worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions). This cycle of relapses and remissions poses unique challenges for disease management.

Key Highlights:

Therapeutic Focus:Current treatments aim to reduce relapse frequency, slow disease progression, and manage symptoms

Emerging therapies include immune-modulating agents, monoclonal antibodies, and next-generation oral drugs.

Pipeline Composition:

A robust pipeline includes over 100 candidates in various phases of development, targeting innovative mechanisms.

Unmet Needs:

While several therapies exist, many have significant side effects or limited efficacy, driving the need for safer and more effective treatments.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/relapsing-remitting-multiple-sclerosis-drug-pipeline-insight/requestsample

Relapsing Remitting Multiple Sclerosis Drug Pipeline Dynamics

Key Drivers Influencing the Pipeline:

Rising Prevalence of MS:

The increasing global prevalence of RRMS has heightened demand for effective therapies.

Focus on Immunomodulation:

Most drugs in development target the immune system, aiming to reduce neuroinflammation and demyelination.

Regulatory Support:

Expedited approvals and orphan drug designations incentivize companies to invest in MS drug development.

Advancements in Molecular Biology:

Improved understanding of the disease's molecular mechanisms has opened new therapeutic targets.

External Relapsing Remitting Multiple Sclerosis Drug Pipeline Trends

Global Trends Driving Market Growth:

Rise of Monoclonal Antibodies:

Therapies like ocrelizumab (anti-CD20) and natalizumab (anti-integrin) are setting the standard for MS treatment.

Collaborative Research:

Partnerships between biotech firms, academic institutions, and pharmaceutical giants are accelerating innovation.

Focus on Oral Therapies:

Oral drugs like fingolimod and siponimod offer convenience and improved patient compliance.

Emergence of Precision Medicine:

Biomarker-driven approaches enable personalized treatment strategies for RRMS patients.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Segmentation

Pipeline Segmentation by Therapeutic Class:

Immunomodulators:

Drugs like interferon-beta and glatiramer acetate modulate the immune response to reduce relapses.

Monoclonal Antibodies:

Target specific proteins to inhibit immune cell activity, such as B-cell depletion.

Next-Generation Oral Therapies:

Focus on reducing neuroinflammation with improved safety profiles.

Pipeline Segmentation by Route of Administration:

Injectables:

Subcutaneous and intramuscular formulations dominate current treatment options.

Oral Medications:

Growing preference for oral drugs due to ease of use and better adherence.

Pipeline Segmentation by Development Phase:

Preclinical Studies:

Investigating novel targets, such as remyelination and neuroprotection pathways.

Phase I, II, and III Clinical Trials:

Assessing safety, efficacy, and optimal dosing regimens.

Pipeline Segmentation by End-User:

Hospitals and Neurology Clinics:

Key centers for administering high-efficacy therapies like monoclonal antibodies.

Outpatient Care Settings:

Focus on long-term management and patient follow-up.

Growth Prospects of the Relapsing Remitting Multiple Sclerosis Drug Pipeline

Factors Driving Market Growth:

Expanding Patient Population:

Increasing awareness and improved diagnostic capabilities lead to earlier detection and treatment.

Innovations in Drug Delivery:

Sustained-release formulations and transdermal patches improve treatment adherence.

Global Investment in MS Research:

Rising funding for neurodegenerative diseases fosters innovation in RRMS drug development.

Pipeline Success:

Promising candidates in late-stage trials are expected to redefine the RRMS treatment landscape.

Recent Developments in the Virus Filtration Market

Virus filtration is critical in the production of biologics and advanced therapies for conditions like RRMS.

Key Advancements:

Enhanced Filtration Technologies:

High-capacity virus filters improve the safety and efficacy of biologic drugs.

Automation and Scalability:

Automated systems streamline production processes, meeting growing demand.

Regulatory Compliance:

Stricter global standards ensure the safety of biologics through improved filtration techniques.

Applications in MS Therapies:

Virus filtration ensures the safety of monoclonal antibodies and other advanced biologics.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis Scope

Key Areas of Focus:

Market Insights:

Analysis of the global RRMS drug market size, revenue forecasts, and regional trends.

Emerging Technologies:

Exploration of innovative drug delivery systems and therapeutic targets.

Competitive Landscape:

Profiling key players, their pipelines, and strategies.

Policy Impacts:

Examination of regulatory frameworks influencing RRMS drug development.

Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis

Comprehensive Insights Include:

Pipeline Composition:

Overview of drugs across therapeutic classes, development phases, and regions.

Clinical Trial Analysis:

Review of ongoing and completed trials, focusing on efficacy and safety outcomes.

SWOT Analysis:

Strengths: Robust R&D focus and regulatory incentives.

Weaknesses: High costs and limited access to advanced therapies.

Opportunities: Expansion into emerging markets and new therapeutic classes.

Threats: Competition and evolving patient needs.

Impact of COVID-19 on Relapsing Remitting Multiple Sclerosis Drug Pipeline

Pandemic Effects on Development:

Clinical Trial Delays:

Disruption in patient recruitment and trial timelines due to restrictions.

Increased Focus on Neurological Health:

The pandemic emphasized the importance of managing chronic diseases like RRMS.

Digital Transformation:

Adoption of telemedicine and remote monitoring enabled continued care and research.

Shift in Research Priorities:

Resources temporarily redirected to COVID-19 impacted the pace of RRMS drug development.

Key Players in Relapsing Remitting Multiple Sclerosis Drug Pipeline

1. Celgene:

A leader in immunomodulatory therapies, focusing on innovative approaches for RRMS treatment.

2. Hoffmann-La Roche:

Pioneering monoclonal antibody therapies like ocrelizumab for MS.

3. Hikma Pharmaceuticals LLC:

Developing cost-effective solutions and biosimilars for MS management.

4. Biogen:

A key player in MS research, with a diverse portfolio of treatments targeting various stages of the disease.

Frequently Asked Questions (FAQ)

1. What is relapsing-remitting multiple sclerosis (RRMS)? RRMS is the most common type of multiple sclerosis, characterized by relapses (periods of worsening symptoms) followed by remissions.

2. What are the current treatments for RRMS? Current treatments include immunomodulators, monoclonal antibodies, and oral therapies targeting neuroinflammation.

3. Why is the RRMS drug pipeline important? The pipeline addresses unmet needs for safer, more effective therapies to improve patient outcomes and slow disease progression.

4. Which companies are leading in RRMS drug development? Key players include Celgene, Hoffmann-La Roche, Hikma Pharmaceuticals LLC, and Biogen.

5. How has COVID-19 impacted RRMS drug research? While delays in trials occurred, the pandemic accelerated digital transformation and increased awareness of managing neurological conditions.

#market research report #healthcare #health and wellness #Relapsing Remitting Multiple Sclerosis Drug Pipeline Analysis

0 notes

stevenwilliam12 · 2 months ago

Text

Global Primary Progressive Multiple Sclerosis (PPMS) Market Overview and Future Outlook - 2032

Introduction

Primary Progressive Multiple Sclerosis (PPMS) is a rare and severe form of multiple sclerosis characterized by a gradual progression of neurological decline without relapses or remissions. This condition predominantly affects adults, and its symptoms can include mobility issues, fatigue, pain, and cognitive decline. Given the complex nature of PPMS and its impact on patients' quality of life, understanding the market dynamics surrounding this condition is critical. This article provides an overview of the current state of the global PPMS market, highlights key trends, and offers insights into future growth prospects through 2032.

Understanding Primary Progressive Multiple Sclerosis (PPMS)

What is PPMS?

PPMS accounts for approximately 10-15% of all multiple sclerosis cases. Unlike relapsing forms of MS, which are marked by episodes of symptoms followed by recovery, PPMS is characterized by a steady progression of symptoms from onset. The exact cause of PPMS remains unclear, but it is believed to involve a combination of genetic, environmental, and immunological factors.

Epidemiology of PPMS

The global prevalence of PPMS varies, but it is estimated that approximately 250,000 to 400,000 individuals are affected by MS in the United States, with PPMS representing a significant subset of these cases. The disease typically presents in middle adulthood, with a slightly higher prevalence in women compared to men. The age of onset and disease progression can vary significantly between individuals, making treatment and management particularly challenging.

Current Trends in the PPMS Market

1. Increasing Awareness and Diagnosis

Growing awareness of PPMS among healthcare professionals and patients has led to improved diagnosis rates. Enhanced diagnostic tools, including advanced imaging techniques and biomarker research, are contributing to earlier and more accurate detection of PPMS. Increased awareness is crucial for timely interventions and management of the condition.

2. Advancements in Treatment Options

Historically, treatment options for PPMS were limited. However, recent advancements in therapies, including the approval of disease-modifying treatments (DMTs) like ocrelizumab (Ocrevus), are changing the landscape for PPMS patients. Ocrelizumab, a monoclonal antibody, has been shown to reduce the progression of disability in PPMS patients, providing hope for better management of the disease.

3. Focus on Personalized Medicine

The trend toward personalized medicine is gaining traction in the management of PPMS. Understanding the individual variability in disease progression and treatment response is leading to tailored treatment strategies that consider genetic, environmental, and lifestyle factors. This approach aims to optimize patient outcomes and enhance the quality of care.

4. Telehealth and Remote Monitoring

The COVID-19 pandemic has accelerated the adoption of telehealth services, providing patients with easier access to healthcare providers. Telehealth is particularly beneficial for individuals with PPMS, as it allows for regular monitoring and management of symptoms without the need for frequent hospital visits. Remote monitoring technologies are also being integrated into care strategies to track disease progression more effectively.

Growth Drivers of the PPMS Market

1. Rising Incidence of Multiple Sclerosis

The global incidence of multiple sclerosis, including PPMS, is on the rise. Factors such as improved diagnostic capabilities, increased awareness, and changing environmental factors contribute to this trend. As more individuals are diagnosed with MS, the demand for effective treatments and support services for PPMS is expected to grow.

2. Investments in Research and Development

Pharmaceutical companies are increasingly investing in research and development to discover new treatments for PPMS. Ongoing clinical trials are exploring novel therapies aimed at halting disease progression and improving patient quality of life. These investments are anticipated to lead to the introduction of innovative treatment options in the coming years.

3. Supportive Policy Frameworks

Government initiatives and policies aimed at improving healthcare access for individuals with chronic conditions are supporting the growth of the PPMS market. Increased funding for MS research and the establishment of specialized MS clinics are crucial for enhancing patient care and outcomes.

4. Growing Patient Advocacy and Support Organizations

Patient advocacy groups and support organizations play a vital role in raising awareness about PPMS and the needs of affected individuals. These organizations are instrumental in promoting research, providing resources, and advocating for policy changes that benefit patients, ultimately driving market growth.

Future Outlook: PPMS Market Forecast to 2032

1. Market Growth Projections

The global PPMS market is projected to witness significant growth, with an estimated compound annual growth rate (CAGR) of approximately 6-8% from 2023 to 2032. This growth is driven by the increasing prevalence of MS, advancements in treatment options, and the rising demand for personalized care.

2. Emerging Therapies and Innovations

The future of the PPMS market is expected to be shaped by emerging therapies, including new DMTs and combination therapies that target multiple aspects of disease pathology. Research into neuroprotective agents and regenerative medicine approaches may also yield promising results in managing PPMS.

3. Continued Focus on Patient-Centric Care

As the healthcare landscape evolves, there will be an increasing emphasis on patient-centric care models that prioritize the needs and preferences of individuals with PPMS. This focus will lead to the development of comprehensive care plans that address not only medical needs but also psychosocial support and lifestyle management.

4. Global Expansion and Access

As healthcare access improves in emerging markets, there will be a growing opportunity for pharmaceutical companies to expand their presence and offer treatments for PPMS. Efforts to increase awareness and access to care in low- and middle-income countries will be crucial for improving outcomes for patients with PPMS globally.

Conclusion

The global primary progressive multiple sclerosis market is at a pivotal point, driven by increasing awareness, advancements in treatment options, and a growing emphasis on personalized care. With the projected growth in the coming years, stakeholders must remain vigilant in addressing the unique challenges faced by individuals with PPMS. Ongoing research, innovative therapies, and collaborative efforts among healthcare providers, researchers, and patient advocacy organizations will be essential in improving the lives of those affected by this debilitating condition. The outlook for the PPMS market through 2032 is promising, with the potential for significant advancements that could transform the management of primary progressive multiple sclerosis.

Latest Reports Offered By DelveInsight:

#PPMS #PPMS Market #PPMS Forecast #PPMS Companies #PPMS Drugs #PPMS Therapies #PPMS Epidemiology #PPMS Pipeline #PPMS Market Size #PPMS Market Trends

0 notes

reportsneww · 2 years ago

Text

Neurological Biomarkers Market is anticipated to exhibit a CAGR of 11.9% from 2022 to 2030

Newark, New Castle, USA – Growth Plus Reports’ most recent study examines the Global Neurological Biomarkers Market’s production, prospective uses, demand, key companies, and SWOT analysis.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/neurological-biomarkers-market/8040

The following are the leading companies in the Global Neurological Biomarkers market:

Abbott Laboratories Inc.

Quanterix Corporation

Thermo Fisher Scientific Inc.

Qiagen NV

Bio-Rad Laboratories Inc.

Merck KGaA

Banyan Biomarkers Inc.

Johnson & Johnson

ACOBIOM

Myriad Genetics Inc.

DiaGenic ASA

Olink Biosciences

Growth Plus Reports studies the key trends in each category and sub-segment of the Neurological Biomarkers market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY TYPE

Genomic

Metabolomic

Proteomic

Imaging

Others

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY APPLICATION

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Others

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY END-USER

Hospitals & Laboratories

Independent Diagnostic Centers

Research Organizations

Others

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/neurological-biomarkers-market/8040

Companies may utilize Neurological Biomarkers market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Neurological Biomarkers industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Neurological Biomarkers market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health’s unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Neurological Biomarkers Market TOC: https://www.growthplusreports.com/report/toc/neurological-biomarkers-market/8040

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

QUICK BUY: https://www.growthplusreports.com/checkout-8040

Browse Latest Healthcare Reports:

Cannabis Drugs Market

Sterilization Wrap Market

Foley Catheters Market

Thrombin Market

Trauma Implants Market

Urinary Drainage Bags Market

Genetic Disease Diagnostics Market

Veterinary Diagnostics Market

Intraoral Scanners Market

Immunodiagnostics Market

Neurodegenerative Disease Drugs Market

Pet Insurance Market

Manan Sethi Director, Market Insights Email: [email protected] Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

About Us Growth Plus Reports is part of GRG Health, a Global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.”

0 notes

tritonmarketresearch · 2 years ago

Text

Alzheimer’s Therapeutics and Diagnostics Market: Expansion Prospects

According to estimates, nearly 5.8 million individuals in the United States were reported to have Alzheimer’s disease (AD) in 2020; and by 2050, this number is expected to surge to 13.8 million individuals. The rising prevalence of this disease across the globe emphasizes the pressing need to develop effective diagnostic methodologies and treatments.

Triton Market Research puts forth that the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is likely to grow with a CAGR of 6.98% in the forecasting period from 2022 to 2028.

Alzheimer’s is a neurodegenerative disease that attacks the neurons, gradually damaging a person’s memory, thinking skills, and ability to perform the simplest daily tasks. People in the age group of 65 years or older are more prone to this condition, as a result of aging. Thus, the rising elderly populace is a key factor driving the demand for AD therapeutics and diagnostics.

Key Diagnostic Methodologies

Computed Tomography leads the Diagnostics segment with a $339.50 million revenue in 2021.

The mortality rate from Alzheimer’s can be minimized if the disease is diagnosed and treated in the early stages. Computed Tomography (CT) is an advanced and cost-effective diagnostic procedure for AD.

As per Medscape, the cost of a CT scan is nearly 20% less than that of an MRI scan

. The benefits offered by this technique and its effectiveness in diagnosing AD are driving the overall segment’s growth.

Blood Test is estimated to grow with the fastest CAGR in the Diagnostics segment, with a 20.93% CAGR during 2022-2028.

Blood testing for AD is an emerging technique that could help detect the disease prior to its onset or in those showing early symptoms. Several players are engaged in developing blood-based tests to identify Alzheimer’s disease biomarkers, as this approach is less invasive and more affordable than the currently available brain imaging and spinal fluid tests. Most of these pipelined products are awaiting marketing approval from the US Food and Drug Administration (FDA) and are most likely to be launched towards the end of the forecast period.

Stringent Regulations – Major Roadblock

According to Alzheimer’s Drug Discovery Foundation, the pharmacological treatment for AD is first tested during clinical trials registered with ClinicalTrials.gov, a registry of publicly & privately funded clinical studies under the National Institutes of Health (NIH). In the US, any company that intends to manufacture a new drug, has to seek approval from the FDA, prior to conducting clinical trials. Similarly, in Japan, companies are required to seek approval from the regulatory body

Pharmaceutical and Medical Devices Agency (PMDA).

The process is extremely cumbersome, as the manufacturers have to submit multiple applications for review before every phase of the trial. Also, post the successful completion of these trials, they must apply for licenses to market the drug. Such stringent regulations for drug development and commercialization are hampering the market’s growth.

Growing Number of Pipeline Drugs – Opportunistic Trend for Therapy

There are several drugs in the pipeline for AD, aimed at cognitive enhancement or neuropsychiatric symptoms control. There are also certain pipeline drugs aimed at preventing, delaying, or slowing the progression of Alzheimer’s. The Alzheimer’s Association estimates that the disease’s prevalence can be reduced by 50% if its onset is delayed by five years. The association further states that, currently, there are 143 drugs in the pipeline for its treatment. In July 2021, Eli Lilly and Company collaborated with Banner Alzheimer’s Institute on the Phase 3 prevention trial for donanemab.

Future Outlook

There is a high potential for developing a superior diagnosis for Alzheimer’s disease, compared to the diagnostic tests available at present. A research article published in Frontiers in Neurology (2020) states that newer techniques, which include the incorporation of PET neuroimaging and other genomics & proteomics biomarkers, are being adopted into revised diagnostic criteria.

Further, significant side effects of medicines and an unexpected lowered patient response towards treatment can be potential application areas for personalized therapy. It allows for a more accurate diagnosis and more effective treatment, with its patient-specific approach. Thus, the emergence of new diagnostic technologies and the development of personalized medicine indicate an overall positive outlook for the Alzheimer’s disease therapeutics and diagnostics market.

#alzheimer disease #Therapeutics #Diagnostic #life sciences #healthcare #market research reports #market research report #triton market research

0 notes

virtualcollectiveparadise · 3 years ago

Text

Global Neuroendocrine Tumor Treatment Market: Industry Analysis and Forecast (2020-2026)

Global Neuroendocrine Tumor Treatment Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 11% during forecast period.

Global Neuroendocrine Tumor Treatment Market Overview:

The improper growth of neoplasms that arise from cells of the numerous endocrine glands and neurological systems causes neuroendocrine tumours. These are commonly called carcinoid tumours because they get infected first in the intestine. Global Neuroendocrine Tumor Treatment Market Dynamics:

Increasing prevalence of Neuroendocrine Tumor is expected to propel the market growth.

Increased incidences of neuroendocrine tumours (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed at a rapid pace in this field. Neurofibromatosis type 1 (NF1), Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), Von Hippel- tuberous sclerosis complex (TSC) and Lindau syndrome (VHL) disease are all increasing the incidence and prevalence of neuroendocrine tumours (NETs) in the United States. Furthermore, according to a study published in the JAMA Oncology Journal in 2017, the survival rate of all neuroendocrine tumour treatments have improved, particularly in the treatment of distant-stage gastrointestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. This is mostly due to the availability of effective medicines and early disease detection.

The market for neuroendocrine tumour treatment is predicted to grow due to the development of new medications. Cancer can be treated in a variety of ways. One of the most popular treatment options for neuroendocrine tumours is targeted therapy. Cancer treatment that uses targeted therapy is quite effective. As a result, targeted NET therapies are predicted to become more popular in the forecast years. Over the forecast period, the market is expected to grow due to an increase in the number of pharmacological approvals for the treatment of neuroendocrine tumours. For example, in January 2018, Novartis Groupe S.A.'s Advanced Accelerator Applications received FDA approval of its new drug application (NDA) for Lutathera for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), which include foregut, midgut, and hindgut neuroendocrine tumours.

The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region. Global Neuroendocrine Tumor Treatment Market Segment Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Product, Indication and End-users.

Based on Product, the Somatostanin Analogs segment is expected to dominate the global market during the forecast period. Somatostanin Analogs (SSAs) are the most commonly utilized medications to treat neuroendocrine carcinoma because they reduce cancer growth, symptoms, and target biomarkers. Because of the safe treatment procedures provided by SSAs, they account for the biggest revenue share. SSAs are commonly utilized to treat patients who have failed to respond to radiation therapy or surgery. As a result, many SSAs are now in clinical trials and awaiting clearance, and the market is likely to grow rapidly over the forecast period. Tarveda Therapeutics' PEN-221 and Dauntless Pharmaceuticals' DP1038 are two examples. Drugs like Sunitinib and Everolimus are used in targeted therapy. These medications are used as the first line of therapy for neuroendocrine carcinoma since they have less negative effects. Chemotherapy, radiation therapy, surgery, and tyrosine kinase inhibitors are among the additional products available.

Global Neuroendocrine Tumor Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Based on Indication, the gastrointestinal segment accounted for the dominant segment in 2019 as NETs are more likely to arise in the GI tract. According to data provided in a Novartis investor presentation in 2015, GI tumours account for 61% of all NETs, with the small intestine tumour being the most common. According to the American Society of Clinical Oncology (ASCO), roughly 8,000 persons in the United States have diagnosed with GI tract-carcinid tumours in 2016. Over the projected period, the rising occurrence of carcinoid tumours in the GI tract is expected to propel the segment forward. Global Neuroendocrine Tumor Treatment Market Regional Insights:

Global Neuroendocrine Tumor Treatment Market Regional Insights

North America is expected to dominate the global market throughout the forecast period.

Because of the increased frequency of neuroendocrine illnesses, developed health care infrastructure, strong clinical pipeline, high level of awareness among individuals, and presence of significant market participants, North America dominates the neuroendocrine tumours market. In this area, there are also supporting insurance programmes, such as Medicare, Medicaid, and Tricare, which make neuroendocrine treatment grow during forecast years. For example, Ipsen got FDA clearance for its Somatuline Depot (lanreotide) Injection 120 mg in December 2014, which is approved for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally progressed or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

In addition, the European neuroendocrine tumour therapy market is predicted to grow significantly over the forecast period, owing to an increase in product approvals by the European Commission (EC) for marketing in European countries.

The report also helps in understanding Global Neuroendocrine Tumor Treatment Market dynamics, structure by analyzing the market segments and project the Global Neuroendocrine Tumor Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neuroendocrine Tumor Treatment Market make the report investor’s guide.

For More Info : https://www.maximizemarketresearch.com/market-report/global-neuroendocrine-tumor-treatment-market/110060/

Global Neuroendocrine Tumor Treatment Market Scope: Inquire before buying

Global Neuroendocrine Tumor Treatment Market Global Neuroendocrine Tumor Treatment Market, by Region:

• North America • Europe • South America • MEA • APAC Global Neuroendocrine Tumor Treatment Market, Key players:

• Novartis AG • Boehringer Ingelheim International GmbH • Pfizer, Inc. • Ipsen Pharma • AVEO Oncology • Hutchison MediPharma Limited • Progenics Pharmaceuticals • F. Hoffmann-La Roche Ltd • Bristol-Myers Squibb Company • Viatris Inc. • Thermo Fisher Scientific Inc. • Regeneron Pharmaceuticals, Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. • Eli Lilly and Company • LUPIN • Advanced Accelerator Applications • BioSynthema Inc. For More Information Visit @:Maximize Market Research Company This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

#Global Neuroendocrine Tumor Treatment Market

0 notes

market-research-future · 3 years ago

Text

biomarker technologies Market Share, Dynamics, Outlook And Segmentation | Forecast to 2027

Market Highlights

The biomarker technologies market is expected to reach USD 78 Billion by 2023 at a CAGR of 9% during the forecast period. The term biomarker is usually used to define a measurable indicator of some biological state or condition. It is also referred to a substance whose detection indicates the presence of a living organism. Biomarkers are used for diagnosis and clinical decision making in cancer, diabetes, and cardiovascular and neurological diseases. The market for biomarker technologies is growing worldwide due to drivers such as increased occurrence of above diseases, advances in the area of medical technologies, governmental initiatives supporting research in the area of biomarker technologies, and increasing uses of biomarkers to increase the accuracy of disease diagnosis. However, high capital investments required for the discovery, development of biomarkers, and the high cost of biomarkers are restraining the growth of the biomarker technologies market.

Regional Analysis

Americas has the largest market share in the biomarker technologies market. The increasing prevalence of cancer, cardiovascular diseases, neurological as well as autoimmune diseases, and rising geriatric population are likely to enhance the growth of the biomarker technologies market. For instance, the National Cancer Institute (NCI) had stated that 1,666,540 new cases of cancer were reported during 2014 in the United States. Thus, this increasing patient pool will enhance the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the biomarker technologies market in the American region. Furthermore, according to CMS (Centers for Medicare and Medicaid Services) the U.S. health care spending increased by 4.3 percent to reach USD 3.3 trillion per person in 2016. Thus, increasing per capita income of individuals as well as rising healthcare spending will aid up the market growth in Americas.

Access Report @ https://www.marketresearchfuture.com/reports/biomarker-technologies-market-6150

Europe is the second largest market leader and holds a healthy share in the global biomarker technologies market. The European market is expected to exhibit a sturdy growth rate during the forecast period owing to the availability of advanced treatment facilities and established healthcare infrastructure, along with the growing need for efficient and accurate diagnosis. Furthermore, according to the Cancer Research U.K., there were around 9, 921 cases of cancer diagnosed in 2015. The increasing occurrence of cancer is expected to have a positive impact on the biomarker technologies market due to its wide usage in cancer. This impact will enhance the biomarker technologies market in Europe.

Asia Pacific is expected to be the fastest emerging market. Factors such as the increasing prevalence of chronic diseases are the major driver for the market growth. For instance, in accordance with the International Diabetes Federation, nearly 382 million people had diabetes in 2013 worldwide. This is expected to reach around 500 million by the end of 2035. China and India are the first and second most affected countries with diabetes. This rising number of diabetic patients can lead to the increasing patient number with cardiovascular diseases. So, these countries are expected to be the fastest growing regions due to the increasing patient pool, raising awareness about health, and availability of new treatment methods.

The Middle East and Africa is expected to witness a limited growth due to limited access to healthcare resources and rising healthcare cost. In the Middle East, the growth of the market is driven by Saudi Arabia and the United Arab Emirates due to increasing research and development for newer technologies and rising healthcare infrastructure.

Segmentation

The global biomarker technologies market is segmented on the basis of product type, profiling technology, disease application, and research areas. Considering product type, the market is segmented into consumables, instruments, services, and software/informatics.

By profiling technology, the market is segmented into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies. Based on immunoassay, the market is again segmented into ELISA, western blot, and protein microarray.

With reference to disease application, the market is segmented into cancer, infectious disease, autoimmune diseases, neurological, cardiovascular disorders, and other disorders.

On account of research areas, the market is segmented into Genomics, Proteomics, Metabolomics, and other research areas. Metabolomics is further segmented into lipidomic and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Key Players

Market Research Future (MRFR) recognizes the following companies as the key players in the biomarker technologies market. Some of the players are Abbott Laboratories, Agilent Technologies (U.S.), Thermo Fisher Scientific (U.S.), Roche (Switzerland), Waters Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Siemens Healthcare, and Bio-Rad Laboratories (U.S.).

Browse Related Reports at:

Blood Collection Market Research Report - Forecast to 2027 | MRFR

Irritable Bowel Syndrome Treatment Market Analysis, Growth Values and Forecast to 2027

Oxygen Therapy Equipment Market by Product, Portability, Applications and Global Forecast to 2027

0 notes

decisionforsight · 3 years ago

Text

Asia Pacific Radiopharmaceutical Market

Asia Pacific Radiopharmaceutical Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

Radiopharmaceuticals are a group of pharmaceutical drugs that contains radioactive isotopes. They are also used as therapeutic and diagnostic agents. Radiopharmaceuticals are used for molecular imaging, involving in the use of these molecules as biomarkers for precise molecular processes that control the progress of a disease. The Asian radiopharmaceutical market is expected to grow rapidly due to increasing awareness among individuals and rising diagnostic rates. This will fuel the demand for SPECT and PET devices in this market. Another factor for its growth is the rise in the number of healthcare facilities and improvement in hospitality. Since most of the countries in this region are developing nations, and working towards the establishment of a stable and efficient healthcare system, it will be an excellent opportunity for the sale of radiopharmaceutical products. APAC Radiopharmaceuticals market was valued at USD 2 billion in 2020 and is expected to be valued at USD 5.6 billion by 2030, witnessing an approximate CAGR of 10.9% over the forecast period.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020159

Market Dynamics and Factors:

Radiopharmaceutical diagnostic techniques offer a better insight into the disease than the conventionally used diagnostic devices, including x-ray, CT, ultrasound, and MRI. Since these diagnostic techniques are new to the developing countries, the scope for the growth is more. On the other hand, strict regulation of the radioactive elements, complex manufacturing processes, and comparatively high prices of the devices are the major restraints. High efficiency, ability to mix with other diagnostic techniques such as x-ray and growing awareness of this technique in the developing market are the major factors expected to fuel the growth of the diagnostic radiopharmaceuticals during the forecast period.

Market Segmentation :

Asia Pacific Radiopharmaceutical Market – By Source

Nuclear Reactors

Cyclotrons

Asia Pacific Radiopharmaceutical Market – By Radioisotope

Technetium-99

Gallium-67

Iodine-123

Iodine-125

18F

Rubidium-82

Yttrium-90

Lutetium-177

Others

Asia Pacific Radiopharmaceutical Market – By Application

Gastro-intestinal

Oncology

Brachytherapy

Others

Nephrology

Cardiology

Neurology

Inflammation

Others

Asia Pacific Radiopharmaceutical Market – By Type

PET/CT

SPECT

Therapeutics

Asia Pacific Radiopharmaceutical Market – By End-User

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Cancer Research Institutes

Others

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020159

Geographic Analysis:

Japan, China, India, Australia, and South Korea, holds major shares of the market in the Asia Pacific due to the production of radioisotopes, out of which Japan is the major producer of the same. The market in Japan is expected to be prominent during the forecast period due to the activities of Sumitomo Corporation, which supplies radioactive raw material to radiopharmaceutical companies. After the introduction of a new accelerator system for the production of radioisotopes in Japan and Australia the radiopharmaceutical market is expected to grow at a higher pace. Some of the factors likely to boost the radiopharmaceutical market in the Asia Pacific are increasing in access to healthcare services, growth in per capita income, rise in demand for radiopharmaceuticals, the surge in the incidence of cancer and heart-related diseases, and speedy introduction of advanced technological systems such as PET/CT, SPECT.

Competitive Scenario:

The major players of the operating in the market are GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt, Siemens Healthiness, Advanced Accelerator Applications, Bayer AG, Eckert & Ziegler, IBA Radiopharma Solutions, Philips, and Jubilant Life Sciences Limited.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020159

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Asia Pacific Radiopharmaceutical industry, although key threats, opportunities and disruptive technologies that could shape the Asia Pacific Radiopharmaceutical Market supply and demand.

The report tracks the leading market players that will shape and impact the Asia Pacific Radiopharmaceutical Market most.

The data analysis present in the Asia Pacific Radiopharmaceutical Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Asia Pacific Radiopharmaceutical Market business.

The 2021 Annual Asia Pacific Radiopharmaceutical Market offers:

100+ charts exploring and analysing the Asia Pacific Radiopharmaceutical Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Asia Pacific Radiopharmaceutical Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020159

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: [email protected]

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

0 notes

techsciresearch · 4 years ago

Text

Precision Medicine Market to Witness 10.65% CAGR until 2026 | TechSci Research

Increasing advancements in cancer biology and myriad benefits offered by precision medicines to drive the global precision medicine market.

According to TechSci Research report, “Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026”, the global precision medicine market was valued at USD66.85 billion in 2020 and is expected to reach USD125.67 billion by registering a CAGR of 10.65% during the forecast period due to shift towards precision medicine, increase in genetic diseases and development of technologies such as next generation sequencing.

Unlike general medicines that are disease-specific and fit for all, the precision medicines focus on the individual diseases. They are patient-based medicines which help the doctors to give optimized treatment to the patients, thereby driving the precision medicine market across the globe. Additionally, international projects such as the Human Genome Project (HGP), funded by the United States government via National Institutes of Health (NIH) are based on precision medicines and provide a deeper understanding of the same. Even though the precision medicines come with an ample number of advantages, they are costly, which might hinder the growth of the market across the globe.

Browse 138 Figures spread through 110 Pages and an in-depth TOC on "Global Precision Medicine Market"

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

The global precision medicine market is segmented based on products and services, technology, application, end user, and region. The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others. Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4684

Customers can also request for 10% free customization on this report.

Some of the leading players in global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX, Inc., and others. In order to sustain the strong competition, companies adopt various strategies like new product launches, collaborations and many more to provide the best precision medicines to the patients. For instance, Novartis has acquired CellforCure, which has expanded its manufacturing capacity for innovative cell and gene therapies.

In June 2020, Thermo Fisher Scientific Inc., the world leader in serving science announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation and create new opportunities for precision medicine.

“In terms of regional analysis, North America dominated the global precision medicine market until 2020, due to favorable government initiatives, heavy investments by the United States in medical research like Human Genome Project (HGP) and growing cases of respiratory and oncology diseases. However, Asia-Pacific region is expected to grow at the highest CAGR through 2026 because of the increasing prevalence of genetic and cancer diseases in countries like China and India” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition, Forecast & Opportunities, 2026” has evaluated the future growth potential of global precision medicine market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global precision medicine market.

Browse Related Reports:

Global Bioinformatics Market By Product & Services (Bioinformatics Tools, Bioinformatic Platforms and Bioinformatic Services), By Type (Genomics & Proteomics, Simulation Studies & Molecular Modelling, Genetic Engineering, Others), By Application (Metagenomics, Drug Discovery, Precision Medicine, Others), By End User (Institutional Research v/s Industrial Research), By Region, Competition, Forecast & Opportunities, 2016-2026F

https://www.techsciresearch.com/report/bioinformatics-market/4279.html

Global Medical Electronics Market By Product Type (Therapeutic and Diagnostics), By End-user (Hospital, Ambulatory Surgical Center, Clinic & Others), By Region (North America, Europe, Asia-Pacific & Others), Competition, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/medical-electronics-market/3896.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Precision Medicine Market #Precision Medicine Market #Precision Medicine Market Size #Healthcare #Precision Medicine Market Share #Precision Medicine Market Forecast #Precision Medicine Market Trend

0 notes

techscimarketresearch · 4 years ago

Text

Precision Medicine Market to Witness 10.65% CAGR until 2026 | TechSci Research

Increasing advancements in cancer biology and myriad benefits offered by precision medicines to drive the global precision medicine market.

Browse 138 Figures spread through 110 Pages and an in-depth TOC on "Global Precision Medicine Market"

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4684

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/bioinformatics-market/4279.html

https://www.techsciresearch.com/report/medical-electronics-market/3896.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Precision Medicine Market #Precision Medicine Market #Precision Medicine Market Size #Precision Medicine Market Share #Precision Medicine Market Forecast #Healthcare

0 notes

merin20 · 4 years ago

Text

How Will The Functional Brain Imaging Systems Market Grow With Technological Advancements?

As per the latest research by PMR, the global functional brain imaging systems market is estimated to account for revenues worth US$ 7 Bn by the end of 2029. The functional brain imaging systems market report also projects a significant growth prospective with a projected average Y-o-Y growth rate of around 7% during the forecast period.

Constant research and development in diagnostic imagining, increased potential of functional brain imaging systems for various neurological disorders and disease applications, coupled with the sanctions of subsidy, and support of government organizations for the R&D of advanced functional brain imaging systems remain the significant factors propelling the growth of functional brain imaging systems market.

Growing Criticality of Effective Diagnostic Imaging

Increase in the incidence of life-threatening diseases and brain injuries has led to the increasing usage of diagnostic procedures. It is estimated that the direct and indirect costs of brain imaging and diagnosis will increase over a period of time. EEG, fMRI and fNRI are the current key advanced products in the brain imaging system market as they have shown reliable results in many diagnostic and therapeutic areas for intracranial hemorrhage, hypoxic-ischemic encephalopathy, and congenital malformation.

Get Going With Sample Of Functional Brain Imaging Systems Market Report! https://www.persistencemarketresearch.co/samples/23050

To fastback the development of cost-effective and efficient medical devices, such as fNRI, fMRI and multi-channel EEG devices etc., various governments in developed and developing countries are facilitating funding for R&D activities in their regions. For instance, in 2018, six research teams were awarded by Brain Canada and Heath Canada for working to improve and change the quality of life of people living with brain disorders and improve healthcare outcomes.

The constantly evolving healthcare diagnostic sector and new measurers for neurological disease management are anticipated to offer new growth opportunities for the global functional brain imaging systems market. Moreover, the growing necessity of intensive care in traumatic brain injury and brain aneurysm is boosting the demand for functional brain imaging systems.

Increasing adoption of functional brain imaging systems for the prevention of brain hemorrhage at ambulatory care centers and hospitals under the guidance of licensed caregivers is also anticipated to boost the functional brain imaging systems market over the forecast period. The introduction of novel radioactive biomarkers, when used with properly tested functional brain imaging systems, is boosting the popularity of the latter among physicians, oncologists, and surgeons. Functional brain imaging systems also find wide acceptance among patients owing to a significant value proposition in the treatment of brain related disorders.

How About Re-Inventing The Methodical Wheel In The Functional Brain Imaging Systems Market? Switch Over To The “Methodology” Tab! https://www.persistencemarketresearch.co/methodology/23050

Manufacturers Seeking Profits through Direct Sales

The manufacturers of functional brain imaging systems are gradually intensifying their focus on providing services and upgrading their facilities to escalate market penetration. In this scenario, dependence on direct sales channels is mounting in economies such as India and China. Visits by direct sales personnel result in opportunities for the training of staff for the proper utilization of functional brain imaging systems for patients. This creates higher efficiency and training protocol for caregivers, which, creates the probability of recurring purchases from end users, which will, in turn, boost the sales of functional brain imaging systems.

A large number of manufacturers of functional brain imaging systems are positioning their products for high-capacity applications in addition to diagnostic procedures and high-complexity operative procedures. Moreover, companies are marketing functional brain imaging systems through direct sales representatives, seminars, brochures, and case studies, to facilitate higher product penetration for different diagnostic applications.

Currently, most of the PET scanning procedures are performed using Fluorodeoxyglucose (FDG), due to its capability to capture higher tissue glucose metabolism. However, FDG also has several shortcomings, the most important one being its specificity. The radiotracer cannot be utilized in the diagnosis of several cancers such as prostate cancer, carcinoma, or brain tumors. Several potential radiotracers are currently under investigation to address the unmet clinical needs of disease diagnosis in the functional brain imaging system market. For instance, Piramal’s diagnostic imaging pipeline includes two radiotracers, 68Ga-RM2 and 68Ga-PSMA (both labelled with radioactive isotope 68 Gallium), for potential use in cancer diagnosis, especially prostate cancer.

Keeping A Tab On Key Players In The Functional Brain Imaging Systems Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our Functional Brain Imaging Systems Market Report! https://www.persistencemarketresearch.com/checkout/23050

PMR has segmented the global market for functional brain imaging systems based on modality, end user, region, and product type. By product type, the market for functional brain imaging systems is further segmented into Magnetoencephalography (MEG) System, Functional MR Imaging (fMRI), Positron Emission Tomography (PET) System, System, Functional near Infrared Spectroscopy (fNIRS) System, and Electroencephalography (EEG) System. On the basis of modality, the functional brain imaging systems market is further segmented into stand-alone device and portable device. On the basis of end user, the functional brain imaging systems market is segmented into office-based clinics, hospitals, diagnostic imaging centers, and ambulatory surgical centers

The report tracks some of the major companies operating in the functional brain imaging systems market, which include Koninklijke Philips N.V., General Electric Company, Canon Medical Systems Corporation, EB Neuro S.p.A., MinFound Medical Systems Co. Ltd, Neurosoft, Medtronic Plc., Nihon Kohden Corporation., Hitachi Medical Systems, Elekta, and Siemens AG.

Explore Extensive Coverage of Persistence Market Research’s Healthcare Industry

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Persistence Market Research Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected]

#Functional Brain Imaging Systems Market Demand #Functional Brain Imaging Systems Market Forecast #Functional Brain Imaging Systems Market Share #Functional Brain Imaging Systems Market Growth #Functional Brain Imaging Systems Market Analysis

0 notes

digitalconvo · 4 years ago

Text

Neurological Biomarkers Market to Register Unwavering Growth During 2028

Global Neurological Biomarkers Market: Snapshot

The population of people affected by a number of neurological conditions has expanded at a rapid pace in the past few years across the globe, making these diseases a leading cause of disability. For the better understanding of these conditions and for the development of more effective personalized medicines, neurology biomarkers have thus been gaining increased attention from the world research fraternity.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=3509

Neurological conditions are mostly diagnoses with the help of markers such as the clinical history of the patient, cognitive testing, neurological examinations, and structural MRIs. However, there are circumstances when the identification of a certain biomarker is necessary for understanding the diagnosis of the condition. Biomarkers are also needed for measuring and evaluating a physiological or pathological indicator for the pharmacological response to a mode of treatment in patients, thus acting as a key basis of developing personalized medicines.

In the past few years, vast improvements have been observed in the understanding of the occurrence and the development of neurological diseases at genomic and epigenomic levels. This has led to rapid developments in the field of neurological biomarkers for the diagnosis of diseases with specific emphasis on the development of personalized medicines. With the rising global demand for personalized medicines, the global market for neurological biomarkers is expected to steadily rise in the next few years.

The vast advancements observed in the healthcare industry and the biomarkers market in the recent years, a number of new companies have forayed into the market. The market for neurology biomarkers has thus witnessed vast advancements such as the introduction of genomics for the better examination of neurological conditions at the generic level. In the next few years as well, the market for neurological biomarkers is expected to exhibit a promising pace of development.

Global Neurological Biomarkers Market: Overview

This report on the global neurological biomarkers market is a comprehensive market intelligence study that brings forth the lucrativeness of the said market. Beginning with an executive summary that comprise a snapshot of how the demand for neurological biomarkers has evolved over the recent past and where is it headed to in the future, the report delves into the analysis of various market dynamics, such as opportunities, trends, challenges, and drivers. A detailed overview of the said market with the analysis of porter’s five forces has been provided in a bid to present a concise and clear landscape of the market vendors to the readers. The market intelligence study also points at mergers, important conglomerates, numerous research and development activities, acquisitions, and corroborations. The said publication allows market stakeholders to study the market in detail and carefully and take well-informed decisions so as to optimize profit and minimize cost.

The world market for neurological biomarkers is expected to grow at a robust CAGR and is anticipated to attain a significant market valuation by the end of the period of forecast.

To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=3509

Global Neurological Biomarkers Market: Trends and Opportunities

Biomarkers are components that are utilized for the purpose of measuring biological states. By definition, a biomarker refers to a naturally occurring gene, molecule, or characteristic by which a particular physiological or pathological process, disease, etc., can be identified. Neurological biomarkers are generally used in the identification of an array of different diseases such as Parkinsons disease, autism, multiple sclerosis, and many others.

The introduction of newer and better neurological biomarkers augments the growth of the world market for neurological biomarkers. In addition to that, expansion in application, technological developments, and rise in the incidence of neurological disorders such as Alzheimers and Parkinsons disease are major factors that have been impacting the world market for neurological biomarkers positively.

Global Neurological Biomarkers Market: Market Potential

The market vendors have been forecasted to obtain new opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the neurological biomarkers manufacturing companies thereby driving further growth of the said market. In addition to that, many of the market participants are anticipated to make a foray into the emerging economies that are yet to be explored so as to find new opportunities.

Global Neurological Biomarkers Market: Regional Analysis

The geographical segmentation of the world market for Neurological Biomarkers is divided into Europe, North America, Latin America, and Asia Pacific. The region of North America comes with a major revenue share in the neurological biomarkers industry as many of the prominent market players are present in this said region, increasing number of projects related to the research & development activities are being carried out and increased government funding received by academic universities to undertake research.

Asia-Pacific is estimated to be one of the fast growing regions as the region makes with an offering of huge based of population, huge aging population, entry of new market players, and high incidence rate of neurological abnormalities. In many of the developing economies such as China and India, new market players are making efforts to establish their market presence by developing the generic version of the biomarker, via contract research organizations. This has further assisted in the reduction of the manufacturing cost for the company and various other production related cost.

Global Neurological Biomarkers Market: Competitive Landscape

A few leading market players that are operating in the world market for neurological biomarkers comprise eminent names such as Cisbio Bioassays, Proteome Sciences, Myriad RBM, Acumen Pharmaceuticals, QIAGEN N.V., Athena Diagnostics, Thermo Fisher Scientific, Abiant, AbaStar MDx, and Aepodia.

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=3509

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States

Tel: +1-415-520-1050

0 notes

crispyobjecttiger · 4 years ago

Text

Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) 2020-2026 which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) Players to battle Covid-19 Impact.

Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) 2020-2026The

Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) 2020-2026

report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version). The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version).

Top Leading players covered in the Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) report : Thermo Fisher Merck Bio-Rad Laboratories Roche QIAGEN Athena Diagnostics Myriad RBM Cisbio Bioassays Wuxi APP BGI Aepodia Genewiz Proteome Sciences and More...

Get PDF Sample Report With Impact of COVID-19 on Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)@

https://www.mraccuracyreports.com/marketreports/7/444/Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

The report offers clear guidelines for players to cement a position of strength in the global Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version). It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) will showcase a steady CAGR in the forecast year 2020 to 2026.

Market Segment by Type covers: Proteomics Genomics Imaging Bioinformatics Others

Market Segment by Application covers: Diagnostics Drug Discovery Personalized Medicine Others

Our Complimentary Sample Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% Discount By Clicking Here!

https://www.mraccuracyreports.com/marketreports/7/444/Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Regions Covered in the Global Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version):

• The Middle East and Africa (GCC Countries and Egypt)

• North America (the United States, Mexico, and Canada)

• South America (Brazil etc.)

• Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

• Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version) Size:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020-2026

Highlights of the Report:

• Accurate market size and CAGR forecasts for the period 2019-2026

• Identification and in-depth assessment of growth opportunities in key segments and regions

• Detailed company profiling of top players of the global Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

• Exhaustive research on innovation and other trends of the global Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

• Reliable industry value chain and supply chain analysis

• Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For Free Download Report:

https://www.mraccuracyreports.com/request/download/7/444/Neurological Biomarkers Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Reasons to buy:

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying Top Manufacturer.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.

Report will be updated with the latest data and delivered to you within 2-4 working days of order.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis.

Create regional and country strategies on the basis of local data and analysis.

Customization of the Report: MR Accuracy Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us: Mr. Marcus Kel Call: +1 804 500 1224 / +44 741841 4646 (International) +91 7448728100 (ASIA) Email: [email protected] Website: www.mraccuracyreports.com"

#Neurological BiomarkersMarket Neurological BiomarkersForecast Neurological BiomarkersIndustry Trends Neurological BiomarkersMarket Share Neu

0 notes

medicaldevicetech · 4 years ago

Text

Vocal biomarkers Market- Trends| Size| Share | Report and Demand

Global Market for Vocal Biomarkers

Non-invasive and early disease detection measures are trending among medical practitioners and patients. Vocal biomarkers are one of the steps forward in this direction. Adopting such practices is increasing the global vocal biomarkers industry share and is estimated to show nearly 14% growth on an annual basis during the projected period. Voice patterns of the patient are observed with vocal biomarkers for detection of any physical and mental disorders.

Request a Sample Copy to Understand the Impact of COVID-19 On Vocal Biomarkers Market

Several factors like unhealthy lifestyle and obesity have increased the rate of chronic health issues on global levels. Early detection of such disorders can save the patient from reaching the point of no return. Authorities are trying to search for such measures which are helping the vocal biomarkers market to boost and stay in form. Apart from medical healthcare uses, vocal biomarkers are also used in lie detection by law enforcement agencies; this has opened an additional field leading to the robust stance of the market.

Both developed and developing economies on a personal basis and with the help of social work organisations are on toes looking for such detection methods. The global vocal biomarkers market is facing problems like unprofessional workforce and storage of data. Its vast usage in other disorders like traumatic brain injury, respiratory problems, neurological disorders and others are propelling the market growth. Research and development programs are vastly working on expanding the uses of vocal biomarkers and are receiving hefty investments from all directions.

Vocal biomarkers Market Segments

There are three segments to this market:

Types: Pitch, error rate, frequency, amplitude, phonation time, vocal rise or fall and other types of vocal biomarkers are available.

Indications: vocal biomarkers are capable of indicating disorders like neurological disorders, psychiatric disorders, respiratory disorders, traumatic brain injury and others.

End-Users: its end users are medical health care providers, law enforcement agencies, academic & research and others.

Vocal biomarkers Market Regional Overview

The global vocal biomarkers market is observed based on four major regions, namely America, Europe, Asia Pacific and The Middle East & Africa.

In the American region, North America is the largest global market with the United States the leader because of the need to adopt latest technology and demands for new non-invasive techniques. Also, there are massive amount shed on the research and development of vocal biomarkers like industries. Europe is the second-largest market due to rising awareness about diseases and their aftereffects. The Asia Pacific stands at the third place as the economies are growing at faster rates leading to rapid industrialisation, embracing new technologies, increased standard of living and increase in per capita incomes. The Middle East & African regions will maintain the slow-growing speeds due to a large pool of weak economies and healthcare facilities.

https://www.marketresearchfuture.com/reports/vocal-biomarkers-market-3933

Recent Industry News

The global vocal biomarkers market is gaining pace due to its cost-effective and non-invasive techniques. There is a need for the skilful workforce to take accurate samples and enhanced storage accommodations. The Asia Pacific is going to emerge as the fastest growing market due to its rapid development and large population counts.

Key players of Global Vocal biomarkers Market:

Key players profiled in the report are Beyond Verbal, Sonde Health, Audio Profiling, IBM Corporation, Cogito Corporation and others.

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

#Vocal biomarkers Market

0 notes

cool-akashy-maximize · 3 years ago

Text

Global Biomarker Technologies Market: Industry Analysis and Forecast (2019-2027)

Global Biomarker Technologies Market was valued at US$ 48 Bn in 2019 and is expected to reach US$ 96.51 Bn by 2027, at a CAGR of 9.12 %during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region.

Global Biomarker Technologies Market

To know about the Research Methodology :- Request Free Sample Report Global Biomarker Technologies Market Dynamics:

The biomarker is used as a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything such as gene, biological molecule, or characteristic that can be used as an indicator of a particular disease state or some other physiological state of a living organism. Biomarker technologies are used in Diagnosis, drug development, and formulation for a contact of definite unsafe chemical and prognostic treatments. The capability of biomarkers to diagnose at an early phase is widely used in cancer analysis and treatment. Biomarkers are using as indicators to estimate and compute pathogenic processes, pharmacological reactions, and biological processes.

The biomarker technologies market is expanding globally under the influence of factors such as increasing incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders. National Cancer Institute (NCI) revealed that approximately 13,397,159 people were affected by various cancer types in the United States in 2011. According to the International Diabetes Federation (IDF), nearly 382 million people were living with diabetes from all over the world in 2013 and this number is expected to reach nearly 592 million by the end of 2035. China and India represent the first and second positions with a high prevalence of diabetes, 98.4 million and 65.1 million respectively.

The growth of the biomarkers market is highly driven by, increasing cases of diseases especially oncology-based disease, increasing demand for disease-specific biomarkers, growing adoption of personalized medicine. Moreover, an increasing utility of biomarkers for diagnostic purposes because of its accuracy, increasing healthcare expenditure, FDA support for biomarkers development, the government taking initiative in more biomarker research, increasing R&D funding by biotechnology companies and research institute, these factors will help to drive the market of biomarkers at XX% CAGR during the forecast period.

On the other hand, a huge amount of capital investment required for the discovery of biomarkers and their development and high cost of biomarkers, this factor may hamper the growth of the biomarkers market during the forecast period. Global Biomarker Technologies Market Segment Analysis:

Based on product type, the consumables segment accounted for the largest market share of biomarkers in 2019 and is expected to dominate over the others during the forecast period owing to the consumables play a key role in biomarker testing. The consumables market is further segmented into reagents & kits and chromatography columns. In 2019, the reagents & kits segment accounted for the largest share of the consumables market.

By profiling technology, the immunoassay segment accounted for the largest share in 2019 and is expected to drive the market of biomarkers in near future. This segment is further divided into ELISA, protein microarray, and western blot. In 2019, the ELISA segment accounted for the largest share of the immunoassay market. ELISA can quantify levels of multiple proteins and have the potential to accelerate the validation of protein biomarkers simultaneously for clinical use, these factors are helpful for the increasing use of ELISA in conformational studies in biomarker discovery.

The omics technology further divided into proteomics, genetics, and transcriptomics. Omics technology is used in the biomarker discovery technologies market. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting, and other molecular applications. The research area is vaster in omics technology Global Biomarker technologies Market Regional Insights:

North America held the largest share of the biomarker technologies in 2019 attributed to the increasing prevalence of diseases such as cancer, autoimmune diseases, cardiovascular diseases & neurological diseases, increasing expenditure on health, and rising geriatric population, these are the factors responsible for the growth of the biomarker technologies market. Europe had the second-largest market in 2019 and holds a healthy share in the global biomarker technologies market owing to the availability of advanced treatment facilities and established good healthcare infrastructure along with the growing need for efficient and accurate diagnosis and an increasing health expenditure the Asia Pacific is expected to register the highest growth rate from 2019 to 2027 for the biomarker technologies market. The rising incidence of cancer, growing geriatric population, and increasing funds in R&D from private and public organizations for biomarker research, are the factors that will drive the growth of the biomarker technologies market in the Asia Pacific region during the forecast period. Recent Highlights in Global Biomarker Technologies Market

A group of chemists from UNSW Sydney’s Australian Centre for NanoMedicine (ACN) and biologists from UNSW's Lowy Cancer Research Centre have created a new sensor named “Nanopore blockade sensor” that can detect disease biomarkers in very low concentration in a short time.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Biomarker Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. Global Biomarker Technologies Market, Key Highlights:

• Global Biomarker Technologies Market analysis and forecast, in terms of value.

• Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Biomarker Technologies Market

• Global Biomarker Technologies Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.

• Global Biomarker Technologies Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.

• Global Biomarker Technologies Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.

• Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.

• Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Biomarker Technologies Market are also profiled.

for more info:https://www.maximizemarketresearch.com/market-report/global-biomarker-technologies-market/31714/

Scope of the Global Biomarker Technologies Market: Inquire before buying

Global Biomarker Technologies Market, by Test Type

• Solid Biopsy • Liquid Biopsy Global Biomarker Technologies Market, by Technology

• ddPCR • NGS • Immunoassay • Mass Spectrometry • DHPLC • Other Technologies Global Biomarker Technologies Market, by Product

• Consumables • Instruments • Services • Software/Informatics Global Biomarker Technologies Market, by Research

• Genomics • Proteomics • Metabolomics o Metabolic Flux o Lipidomics o Others • Other Research Areas Global Biomarker Technologies Market, by Application

• Drug Discovery • Diagnostics • Personalized Medicine Global Biomarker Technologies Market, by Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America Key Players Operating in the Global Biomarker Technologies Market:

• Thermo Fisher Scientific • Bio-Rad Laboratories • Danaher Corporation • Agilent Technologies • Roche • Waters Corporation • Shimadzu Corporation • Illumina, Inc. • F. Hoffmann-La Roche AG • Merck KGAA • PerkinElmer Inc. • Siemens Healthcare • Abbott Laboratories • Qiagen N.V. • Biomérieux SA, • Becton, • Myriad Genetics, • Sysmex Corporation, • Quest Diagnostics • Aushon BioSystem Inc., • Epistem Ltd. • Hologic

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

0 notes

techsciresearch · 3 years ago

Text

Diagnostic Imaging Equipment to dominate the United States Medical Devices Market

New product launches and rising prevalence of chronic diseases is expected to drive the United States medical devices market for the forecast period.

According to TechSci Research report, “United States Medical Devices Market By Type (Cardiovascular Devices, Diagnostic Imaging Equipment, In-vitro Diagnostic Devices, Opthalmic Devices, Diabetes Care Devices, Dental Care Devices, Surgical Equipment, Orthopedic Devices, Nephrology & Urology Devices, ENT Devices, Anesthesia & Respiratory Devices, Neurology Devices, Mobility-Aid Devices, Others) By End User (Hospitals & Clinics, Diagnostic Centers, Others) By Company, By Region, Forecast & Opportunities, 2026”, The United States medical devices market is expected to witness significant growth for the next five years. Medical devices consist of apparatus, machines, articles, or instruments which are used in diagnosis, treatment and prevention of diseases or health-disorders of patients. Discovery of injectable pens for treatment of diseases including diabetes, arthritis, anaphylaxis, other hormone deficiency, osteoporosis is expected to drive the medical devices market growth. Favorable government policies have played a positive role for the growth of the bronchoscope market. Some of the bronchial procedures are bronchial or endobronchial biopsy, rigid and flexible bronchoscopy and bronchoalveolar lavage. Rising cases of lifestyle disorders, injuries and accidents are accelerating the market growth. Increasing adoption of mobile surgery centers and demand for effective and quick emergency treatment is further boosting the growth of the medical devices market.

The COVID-19 outbreak across the world which has been declared as pandemic by World Health Organization has affected countries adversely. Leading authorities in United States imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. Coronavirus affected patients started suffering from shortness of breath along with coughing and sneezing which created lucrative opportunities for the growth of the respiratory care devices market. United States authorities increased the capacity of hospitals as a greater number of patients were getting affected daily and getting admitted into the hospital facilities. Growth in demand for consumable medical devices to cope up the prevailing conditions of pandemic such as pulse oximeter, gloves, testing kits, personal protection equipment kit, ventilators, oxygen concentrators is on rise. The continuous demand for medical devices for treatment of patients is expected to fuel the market growth for the predicted period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "United States Medical Devices Market”

https://www.techsciresearch.com/report/united-states-medical-devices-market/7484.html

United States medical devices market is segmented into type, end user, regional distribution, and company. Based on type, market is further divided into cardiovascular devices, diagnostic imaging equipment, in-vitro diagnostic devices, opthalmic devices, diabetes care devices, dental care devices, surgical equipment, orthopedic devices, nephrology & urology devices, ENT devices, anesthesia & respiratory devices, neurology devices, mobility-aid devices, and others. The diagnostic imaging equipment segment is expected to account for major market share for the forecast period, 2022-2026. Increasing prevalence of chronic diseases requires long term treatment in healthcare facilities and benefits of early diagnosis and treatment of diseases is fueling the demand for medical devices market for the next five years. Healthcare sector witness arrival of foreigners for availing top-notch healthcare facilities in United States. High-end investments by market players and leading authorities and supportive reimbursement structure are bolstering the growth of the diagnostics imaging equipment segment growth. Also, an increase in trauma and sports related injuries is fostering the growth of the medical devices market in United States.

GE Healthcare, Siemens Medical Solutions USA Inc., Philips Healthcare USA, Shimadzu Medical Systems USA, Hologic, Inc., Fujifilm Medical Systems USA, Medtronic USA, Inc., Johnson & Johnson, Abbott Laboratories, Inc., Becton, Dickinson, and Company, Baxter International, Inc., Canon Medical Systems USA, Inc., Bausch Health Companies, Inc., Alcon, Inc., Dexcom, Inc., Hill-Rom Holdings, Inc., ResMed, Inc., Invacare Corporation, Roche Diagnostics Corporation, Stryker Corporation are the leading players operating in United States medical devices market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several medical devices manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7484

Customers can also request for 10% free customization on this report.

“Innovations in technology and collaborations between market players have led to advances in wearable electronic devices, robotic technology, biomarkers, neuro-stimulators, stent technologies which has significantly improved the medical devices market in United States. Adoption of latest technology such as internet of things, artificial intelligence, 3D printing, big data analytics is creating huge opportunities for the growth of the medical devices market for the forecast period. Increasing demand for advanced medical devices and surging life expectancy of people is expected to accelerate the medical devices market growth until 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Medical Devices Market By Type (Cardiovascular Devices, Diagnostic Imaging Equipment, In-vitro Diagnostic Devices, Opthalmic Devices, Diabetes Care Devices, Dental Care Devices, Surgical Equipment, Orthopedic Devices, Nephrology & Urology Devices, ENT Devices, Anesthesia & Respiratory Devices, Neurology Devices, Mobility-Aid Devices, Others) By End User (Hospitals & Clinics, Diagnostic Centers, Others) By Company, By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of United States medical devices market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of United States medical devices market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web: https://www.techsciresearch.com/

#United States Medical Devices Market #United States Medical Devices Market Size #United States Medical Devices Market Share

0 notes